Cellular senescence is a well-established cancer defence mechanism that has also been proposed to have roles in ageing and age-associated diseases, presumably through the depletion of stem and progenitor cells, and the adverse actions of the senescence-associated secretory phenotype, which consists of many proinflammatory cytokines and chemokines, matrix metalloproteinases and growth factors 1-3 . Consistent with this idea is the observation that interference with senescent cell accumulation in BubR1 progeroid mice delays several of the ageing-associated disorders that these animals develop 4,5 . However, because progeroid syndromes do not mimic the complex degenerative changes of ageing completely, the relevance of these findings has remained unclear. Furthermore, recent studies showing that senescent cells have beneficial effects in injury repair and tissue remodelling 6-10 have called into question the simplistic view of senescence as only a driver of age-dependent pathologies, raising the specter that senescent cell clearance might remove useful cells in addition to detrimental ones. Here we investigated the identity and physiological effect of naturally occurring senescent cells using INK-ATTAC (hereafter termed ATTAC) 4 , a transgenic mouse model that expresses the FK506-bindingprotein-caspase 8 (FKBP-Casp8) fusion protein and green fluorescent protein (GFP) under the control of a minimal Ink4a (also known as Ink4a/Arf or Cdkn2a) promoter fragment transcriptionally active in senescent cells 4,11 . Earlier we have shown that, in BubR1 progeroid mice, ATTAC ablates p16 Ink4a -positive senescent cells upon administration of AP20187 (AP), a dimerizer that activates FKBP-fused Casp8 (ref. 4). Our first objective was to validate the properties of ATTAC in naturally occurring p16 Ink4a -positive senescent cells.
Adipose tissue of young ATTAC mice lacked SA-β-Gal activity but contained p16 Ink4a (Extended Data Fig. 1a , f-h). This p16 Ink4a pool did not decline after AP treatment. Similar results were obtained with early passage ATTAC MEFs (Extended Data Fig. 1i-k) , indicating that baseline Ink4a promoter activity in non-senescent cells is insufficient for FKBP-Casp8-mediated apoptosis. Furthermore, ATTAC lacks Ink4a promoter elements required for transgene induction in replicating pre-neoplastic cells that robustly express endogenous Ink4a owing to Rb inactivation and AP fails to kill these cells (Extended Data Fig. 2a-g) . ATTAC was also not induced in peripheral blood T lymphocytes that robustly engage endogenous Ink4a with ageing without concomitant expression of several senescence markers 2, 13 (Extended Data Fig. 2h ), further indicating that transgene induction is selective for senescence. However, these limited analyses certainly do not exclude the possibility that other Ink4a-positive non-senescent cells engage ATTAC and die after AP exposure (Supplementary Information).
Clearance by ATTAC is partial and tissue selective
To extend our analysis of the properties of ATTAC, we analysed the transcript levels of Ink4a, FKBP-Casp8, GFP and a panel of senescence markers in a broad spectrum of tissues of 2-, 12-and 18-month-old untreated ATTAC mice, including skeletal muscle, eye, kidney, lung, heart, liver, colon and spleen. ATTAC mice treated with AP between 12 and 18 months were included to assess senescent cell clearance rates. Ink4a expression markedly increased between 12 and 18 months in all tissues examined, which coincided with the induction of FKBP-Casp8, GFP and several senescence markers (Extended Data Fig. 3a ). Increased expression of these transcripts was blunted to varying degrees by AP treatment in all tissues examined except colon and liver, indicating that the ATTAC system eliminates Ink4a-positive senescent cells in a partial and tissue/organ selective fashion. Blunting of age-dependent increases in Il6, Il1a and Tnfa expression in fat, skeletal muscle and kidney by AP treatment (Extended Data Fig. 3b ) suggests that Ink4a-positive cell clearance ameliorates inflammation in these tissues.
p16 Ink4a+ cells shorten lifespan and healthspan
To examine the effect of p16 Ink4a -positive cell clearance on health and lifespan, we sequentially established two cohorts of ATTAC transgenic mice (Fig. 2a ). The initial cohort was on a C57BL/6-129Sv-FVB mixed genetic background fed a diet containing 9% fat. We note that this diet shortens lifespan compared to diets with 5% fat typically used in lifespan studies (Extended Data Fig. 4a, b and Supplementary Information). The later cohort was on a congenic C57BL/6 background fed a standard 5% fat diet. At 12 months of age, when p16 Ink4a+ cells started to accumulate in several tissues (Extended Data Figs 1d and 3a) , mice were injected twice a week with AP or vehicle until they became moribund or died of natural causes. Mice separate from the longevity cohorts were examined for a series of age-sensitive outcomes at . p21 is also known as Cdkn1a; Pai1 is also known as Serpine1. c, SA-β-Gal activity in GFP + and GFP − iWAT cells (n = 3 mice). d, GFP + cells in the indicated iWAT (IAT) cell populations ('rest' represents the iWAT vascular stromal fraction minus leukocytes, endothelial cells and progenitors). e-i, Fatrelated analyses of C57BL/6 ATTAC mice before treatment (12 months) or after 6 months of treatment with vehicle (18 months −AP) or AP (18 months +AP). e, SA-β-Gal activity in iWAT and epididiymal WAT (eWAT). f, Electron micrograph showing perivascular X-Gal-positive cells from an 18-month-old vehicle-treated C57BL/6 ATTAC male. A, adipocyte; C, capillary. Arrows mark endothelial cells. g, Quantification of iWAT cells containing X-Gal crystals (n = 4 mice per treatment). h, Fat mass measurements. i, iWAT and eWAT depot weights. j, Mean adipocyte diameters in iWAT. k, Expression of adipogenesis markers in iWAT (n = 4 mice per group). Scale bars, 10 μm (c), 0.5 cm (e), 2 μm (f) and 200 nm (f, inset). Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001 (one-sample t-tests using a theoretical mean of 1 (b), and unpaired two-tailed t-tests (c, d, g-k)).
Survival (%)   300  500  700  900 1,100   0   25   50   75   100   300  500  700  900 1,100 300  500  700 Healthspan analysis was done at 18 months, an age at which relatively few mice in vehicle (Veh.)-or AP-treated groups have died, and bias owing to selection for long-lived animals is unlikely. b, c, Survival curves for vehicle-treated (−AP) and AP-treated (+AP) mixed (b) and C57BL/6 (C57; c) mice. Median survival (in days, d) and percentage increase in median survival are indicated. We note that median lifespans of our vehicle-treated cohorts are similar to those of wild-type mice administered AP (c). *P < 0.05; **P < 0.01; ***P < 0.001 (log-rank tests).
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18 months, an age at which relatively few mice in each of the cohorts had died. Data for both sexes combined showed that median lifespans of mixed and C57BL/6 AP-treated animals were increased by 27% and 24%, respectively. Median lifespans for each sex separately were also significantly extended in AP-treated cohorts irrespective of genetic background, with increases ranging from 17% to 35% (Fig. 2b, c) .
Maximum lifespan 14 was significantly increased for mixed AP-treated males and females combined (P = 0.0295), but not for females and males individually. Maximum lifespan was not extended for C57BL/6 AP-treated animals, either combined or separately. Importantly, AP treatment of mice lacking the ATTAC transgene did not improve lifespan ( Fig. 2c ). We note that the median lifespan of vehicletreated C57BL/6 males, but not females, was short of the normal range of lifespans for unmanipulated males of this strain at different laboratories [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] (Extended Data Fig. 4c, d ), suggesting that repetitive vehicle injection stress may have negatively affected C57BL/6 male longevity (Supplementary Information).
In both cohorts, AP treatment had no effect on the incidence or spectrum of macroscopically detectable tumours at autopsy, although tumour latency was increased ( Fig. 3a and Extended Data Fig. 5a-d ). Median lifespan extensions of AP-treated mice dying without tumours ranged from 24% to 42% (Extended Data Fig. 5e ), indicating that increased longevity was not merely due to a tumour-protective effect. AP-treated mice were overtly indistinguishable from vehicle-injected littermates at 18 months of age, but typically had a healthier appearance by 22 months (Fig. 3b ). AP treatment delayed cataract formation in both males and females on a C57BL/6 background (Extended Data Fig. 5f , g). Despite a lack of overt difference at 18 months, AP-treatment prevented age-dependent reductions in both spontaneous activity and exploratory behaviour measured by open-field testing ( Fig. 3c ), which was independent of sex and genetic background.
Extended tests on these mice showed no differences in motor coordination and balance, memory, exercise ability or muscle strength (Extended Data Fig. 6 ), indicating that 6 months of p16 Ink4a -positive cell clearance did not affect these age-sensitive traits. Similarly, agerelated changes in the circulating haematopoietic profile, including regulatory T-cell levels, were also not affected (Extended Data Fig. 7 ). At 18 months, fasting glucose levels, glucose tolerance, insulin sensitivity and circulating Igf1 levels were not significantly different in AP-and vehicle-treated C57BL/6 ATTAC females, as was signalling downstream of Igf1 and insulin receptors in fat, kidney and muscle, three tissues where we observed clearance of p16 Ink4a+ cells (Extended Data Fig. 8 ).
Renal epithelial cell senescence and glomerulosclerosis
To further investigate the effect of p16 Ink4a+ cells on physiological functions that change with age 29 , we focused on kidney and heart, two vital organs in which we observed ATTAC-mediated clearance. Aged kidneys are characterized by the formation of sclerotic glomeruli, which affect glomerular filtration rates, impair kidney function, and lead to increased blood urea nitrogen levels 30, 31 . Indeed, glomerulosclerosis significantly increased between 12 and 18 months in vehicle-treated ATTAC mice. AP treatment markedly reduced glomerulosclerosis independent of sex and genetic background ( Fig. 4a, b ), which correlated with attenuated age-related increases in blood urea nitrogen ( Fig. 4c ), indicating preserved kidney function. SA-β-Gal staining of kidney sections confirmed that AP-mediated disposal of senescent cells was quite efficient (Fig. 4d ). By TEM, we observed X-Gal crystals in 0.3% and 1.2% of renal cells of 18-month-old treated and untreated mice, respectively ( Fig. 4e, f) . Surprisingly, SA-β-Gal + cells were not located in the glomeruli but in proximal tubules ( Fig. 4e ), raising the question as to how senescent tubular brush-border epithelial cells might promote glomerulosclerosis.
Angiotensin receptor blockers attenuate age-related glomerulosclerosis under normotensive conditions, which has led to the idea that overactivation of the local renin-angiotensin-aldosterone system (RAAS) drives the formation of sclerotic glomeruli 31, 32 . Consistent with this, kidney transcript levels of a key component of this system, angiotensin receptor 1a (Agtr1a), increased between 12 and 18 months ( Fig. 4g ). By contrast, no such increase was observed in AP-treated mice. Western blotting confirmed that Agtr1a protein levels were lower in AP-treated kidney samples (Fig. 4h ). Both renal tubules and glomeruli contributed to this decline, as demonstrated by immunolabelling of kidney sections for Agtr1a ( Fig. 4i ). These data suggest that senescent renal epithelial cells may produce senescence-associated secretory phenotype components that hyperactivate the local RAAS in kidney.
p16 Ink4a+ cells contribute to cardiac ageing
Hearts of 12-month-old mice showed SA-β-Gal activity at the atrial and ventricular surface ( Fig. 5a ), which increased with ageing in vehicletreated but not AP-treated mice. TEM revealed that ciliated epithelial cells and fibroblasts in the pericardium contained X-Gal crystals ( Fig. 5b, c) . We also observed SA-β-Gal + smooth muscle cells in the aortic root wall of vehicle-treated animals ( Fig. 5a and Extended Data Fig. 9a ). At 18 months, vehicle-and AP-treated ATTAC mice analysed by echocardiography showed no significant differences in heart rate, left ventricular mass, thickness and diameter, ejection fraction and fractional shortening, all of which were also unchanged from 12-month-old mice (Extended Data Fig. 9b-g) . Cardiac ageing at the histological level is characterized by a loss of ventricular cardiomyocytes due to decreasing ability to replace apoptotic or necrotic cardiomyocytes, inducing hypertrophy of the remaining cardiomyocytes 33 . Morphometric analysis of heart sections showed that ventricular wall thickness was the same in vehicle-and AP-treated animals, regardless of sex ( Fig. 5d ). Ventricular cardiomyocytes of AP-treated mice, however, were much smaller ( Fig. 5e, f ), suggesting that they had more cardiomyocytes than vehicle-treated mice. Taken together, these data suggest that p16 Ink4a -positive cells are key drivers of this age-related cardiac phenotype.
Cardiac ageing is also characterized by decreasing stress tolerance, which has been attributed to decreasing numbers of ATP-sensitive potassium (K ATP ) channels in the sarcolemma of cardiac myocytes due to age-related reductions in the expression of Sur2a, a key Article reSeArcH regulatory subunit of K ATP channels 34 . Cardiac Sur2a (also known as Abcc9) expression indeed decreased between 12 and 18 months in vehicle-treated mice (Fig. 5g ), but no such decline was observed in AP-treated mice, suggesting that cardiac stress tolerance was preserved. To test this, we measured the time to death from arrhythmogenesis after injection of 580 mg kg −1 of the β-adrenergic agonist isoproterenol 35 . Consistent with age-related loss of cardiac stress resistance, 18-monthold vehicle-treated mice died faster than 12-month-old mice (Fig. 5h ). By contrast, the time to death was not accelerated in AP-treated mice. In a second, more physiological stress test, we conducted echocardiographic measurements of ventricular mass before and after eliciting cardiac stress over a 6-day period, by administering 10 mg kg −1 isoproterenol twice a day. Cardiac mass significantly increased in 18-monthold vehicle-treated mice, whereas AP-treated mice were capable of handling the applied stress without such adaptive response, similar to young mice (Fig. 5i ).
We also examined whether AP-treatment caused any off-target or detrimental effects. Wild-type mice lacking ATTAC did not show healthspan improvements when treated with AP (Extended Data Fig. 9h-l) . Consistent with a beneficial role of senescent cells only for the duration of wound repair 6-8 , 18-month-old AP-treated ATTAC mice repaired cutaneous wounds when drug administration was suspended during healing (Extended Data Fig. 10a-c) . When AP was administered during wound closure, healing was delayed with similar kinetics as 4-or 18-month-old ATTAC mice without previous AP treatment, indicating that acute senescence mechanisms are preserved with ageing and not influenced by constitutive clearance of senescent cells 3 . Furthermore, 18-month-old AP-treated mice showed no evidence of increased fibrosis in skin and other tissues, despite a role for senescent cells in limiting fibrosis during tissue repair (Extended Data Fig. 10d ).
Discussion
Here we eliminated p16 Ink4a+ cells from non-progeroid mice using ATTAC to begin to address how senescent cells influence health and lifespan. We observe median lifespan extensions in AP-treated ATTAC mice on two distinct genetic backgrounds and diets, indicating that age-related accumulation of p16 Ink4a+ cells negatively affects longevity. It will be useful to optimize senescent cell removal protocols and methods further because the longevity of male C57BL/6 mice seemed negatively affected by repetitive vehicle injection stress, and because clearance was partial and several key tissues were refractory to clearance, including liver and colon. This would be particularly relevant for further studies of maximum lifespan, extension of which is thought to be reflective of a more generalizable 'anti-ageing' effect 29 (Supplementary Information).
These methodological caveats aside, we find that removal of p16 Ink4a+ cells from midlife on delays the progression of neoplastic disease irrespective of genetic background and diet. Clearance had no effect on the spectrum or incidence of post-mortem tumours, which is consistent with the hypothesis that senescent cells help create a tissue microenvironment that promotes tumour progression 1 . In addition, several age-dependent changes 29 , including alterations in fat, eye, heart and kidney, as well as the age-dependent decline in spontaneous activity and exploratory behaviour, occur more slowly during a six-month period of p16 Ink4a+ cell clearance starting at midlife. Complementary mechanistic studies suggest that local p16 Ink4a+ cells in fat, kidney and heart exert their effects through distinct mechanisms, involving progenitor cell dysfunction, RAAS overactivation, and Sur2a downregulation, respectively, although systemic effects cannot be excluded given the global nature of the clearance method applied here.
Thus, our data best fit a model in which p16 Ink4a+ cells act to shorten healthy lifespan by promoting tumour progression and age-dependent changes that functionally impair certain tissues and organs, including vital organs such as kidney and heart. This, together with the key observation that elimination of p16 Ink4a+ cells is not associated with any overt detrimental effects raises the possibility that this approach may be useful to treat aspects of age-related functional decline, age-related diseases that involve senescent cells, or side effects of therapies that create senescent cells 36 .
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MethODS
Mouse strains and drug treatments. All studies described using ATTAC mice were performed on transgenic line 3, which contains 13 copies of the transgene inserted into a single locus (data available on request). The generation and characterization of the ATTAC transgenic line has been previously described in detail 4 . Two cohorts of ATTAC mice were consecutively established and analysed. The first cohort consisted of mice on a mixed 129Sv (40% ± 5%) × 57BL/6J (35% ± 5%) × FVB (20% ± 5%) genetic background as determined by Harlan Laboratories using established single nucleotide polymorphism (SNP) panels ( Supplementary Table 1 ). These mice were fed an irradiated pelleted breeder chow diet ad libitum for the entire duration of the study: LabDiet product 5058, with 9% fat content (21.635% calories from fat). Mice from this cohort were randomly assigned to be injected with AP20187 (AP; B/B homodimerizer, Clontech) or vehicle twice a week beginning at 12 months of age. Dosing was 0.2 μg AP20817 per g body weight between 12 and 18 months (the same dose as previously used for senescent cell clearance in BubR1 progeroid mice; see ref. 4) , and 2.0 μg AP per g body weight from thereon. The second cohort was established ~1.5 years later after completion of ATTAC line 3 backcrossing onto a pure C57BL/6J genetic background (Jackson Lab stock number 000664). Detailed breeding information for the C57BL/6 ATTAC cohort is provided in Supplementary Table 2 . For the entire duration of the study, congenic ATTAC transgenic mice were maintained ad libitum on standard irradiated pelleted chow diet: LabDiet product 5053 with 5% fat content (13.205% calories from fat). The number of mice in the C57BL/6J cohort was increased compared to the mixed cohort to allow for more comprehensive healthspan analyses at 18 months of age. The C57BL/6J cohort was randomly assigned to receive either 2.0 μg AP per g body weight or vehicle from 12 months until the end of life. Non-transgenic mice from C57BL/6J ATTAC transgenic crosses were used to establish the control cohort for confirmation that AP had no effect on healthspan in the absence of the ATTAC transgene. BubR1 H/H ;ATTAC mice used in this study were generated as previously described 4 . Animals were housed in a pathogen-free barrier environment throughout the duration of the study and kept on a 12-h light-dark cycle. Specifically, mice were housed 5 per cage in static autoclaved HEPA-ventilated microisolator cages measuring 446 cm 2 (27 × 16.5 × 15.5 cm), which are opened only within class II biosafety cabinets. Restricted entry to the room requires key card access to unlock the door. Entrance into the barrier facility requires wearing autoclaved gowns, disposable gloves, caps and shoe covers. Personnel are not allowed to enter any other rodent facility before entry into the barrier. Mouse colonies in this facility are monitored through contact sentinels (one cage per rodent rack), which are evaluated quarterly for (and are free of) the following agents: Sendai virus, pneumonia virus of mice (PVM), mouse hepatitis virus (MHV), minute virus of mice (MVM), Theiler's murine encephalomyelitis virus (TMEV strain GDVII), reovirus, rotavirus (EDIM), mouse parvovirus (MPV strain 1 and 2), murine norovirus (MNV), Mycoplasma pulmonis, Aspiculuris tetraptera and Syphacia spp. In addition, the following are annually screened for (and free of) these agents: lymphocytic choriomeningitis virus (LCMV), ectromelia virus (mousepox), K virus, polyoma virus, mouse adenovirus (MAV type 1 and 2), hantavirus, Prospect Hill virus (PHV), mouse cytomegalovirus (MCMV), lactate dehydrogenase elevating virus (LDEV) Encephalitozoon cuniculi, cilia-associated respiratory bacillus (CARB), mouse thymic virus (MTV, MTLV), Clostridium piliforme, Myobia spp. and Myocoptes spp. Autoclaved Enrich-o'Cobs (The Andersons Incorporated) were used as bedding. Cages and bedding were changed weekly. Mice had ad libitum access to municipal city water that was sterilized with ultraviolet light. Room temperature was maintained between 21 °C and 23 °C. Ear tags (1005-1, National Band and Tag Co.) were applied to pups at the time of genotyping for identification purposes. All animal procedures were approved by the Mayo Clinic Institutional Animal Care and Use Committee. Statistical analysis. Prism software was used for statistical analysis and generation of survival, cataract and tumour latency curves. Two-tailed unpaired t-tests were used for pairwise significance unless otherwise indicated. log-rank tests were used for survival, cataract and tumour latency curves. For maximum lifespan extension analysis, two-sided Wang-Allison tests were used 14 . For consistency in these comparisons, the following denotes significance in all figures: *P < 0.05, **P < 0.01 and ***P < 0.001. We note that no power calculations were used. Sample sizes were based on previously published experiments where differences were observed. No samples were excluded. Investigators were blinded to allocation during experiments and outcome assessment, except for rare instances where blinding was not possible.
Single-cell preparations and flow cytometry.
To determine the cell type origin of senescent cells accumulating in fat, we prepared single cells from iWAT, collected the stromal vascular fraction by centrifugation and labelled the resulting cells with specific cell surface markers for collection of the CD45 + , endothelial, and progenitor (adipocyte stem cells plus preadipocytes) cell populations by FACS as previously described 4, 35, 37 . To quantify progenitor cells, we divided the number of progenitors recovered from the stromal vascular fraction by the total number of cells in the stromal vascular fraction. Single cell preparations from wounds were prepared in a similar manner. The proportion of GFP + cells in each population was assessed using flow cytometry as described 4 . Analysis of age-related phenotypes. Bi-weekly checks for cataracts were performed as described 5 . iWAT cell diameter, adipose depot weight, skin thickness, and skeletal muscle diameter measurements were as described 4 . Open fieldtesting was performed in a 50 cm × 50 cm box and analysed with TopScan software (CleverSys Inc.). Sclerotic glomeruli and blood urea nitrogen assessments were performed as described 38 . To determine cardiomyocyte cross-sectional area, three sagittal sections of the mid-ventricle separated by 400 μm were stained with periodic acid-Schiff using a kit (Poly Scientific R&D, k098). At least 150 cardiomyocytes in the left ventricular free wall per section were measured using Image J software. Lethal isoproterenol challenges were performed as described 38 . Parameters of cardiac function were determined with echocardiography using Vevo2100 Imaging System (VisualSonics Inc.) with a 30 mHz transducer. Mice were lighly anaesthetized by isoflurane (0.8-1.5%) with minimal effect on heart rate. Several m-mode recordings of the cardiac parasternal short axis at the level of papillary muscles were made and subsequently analysed. For non-lethal isoproterenol challenge, mice were analysed at baseline (day 0) and subsequently were administered five consecutive days of treatment with 10 mg kg −1 twice daily as described 39 . Mice were then assessed for alteration in LV mass on day 6. For longitudinal measurements of cardiac structure recordings were acquired in conscious animals. At least three different recordings per animal at each time point were analysed. Rotarod assessments were as previously published 40 . Exercise ability was performed as described 4 . Novel object discrimination tests were performed as described 41 . Grip strength was determined as previously published 42 . Gross haematology was assessed by analysing EDTA-treated whole blood using a Hemavet 950 (Drew Scientific Inc.). FACS-based analyses of peripheral blood leukocyte populations were as previously described 43 . CD3 + T lymphocytes were collected from peripheral blood (isolated using CD3 MicroBeads and MACS columns purchased from Miltenyi Biotec) according to manufacturer's instructions. Glucose tolerance was assessed in mice fasted overnight by measuring blood glucose levels before and at time points after an intraperitoneal injection of glucose (1.0 g kg −1 ). Insulin sensitivity was measured following a 4 h fast by measuring blood glucose levels before and at time points after an intraperitoneal injection of insulin (0.6 mU g −1 ). Serum Igf1 concentrations were measured by ELISA according to manufacturer's instructions (R&D Systems, MG100). Wound healing assessments were performed as previously described 44 . Phosphotungstic acid haematoxylin (PTAH) staining on formalin-fixed, paraffin-embedded tissue samples was performed as described previously 35 . Quantitative PCR. RNA extraction, cDNA synthesis and qRT-PCR analysis of various mouse tissues and CD3 + T lymphocytes collected from peripheral blood were performed as described 5 . RNA extraction from cell lines was performed according to manufacturer's instructions (Qiagen RNeasy mini kit). Sequences of primers for FKBP-Casp8, Egfp, Ink4a, Arf, p21, Il6, Pai1, Igfbp2 and Mmp13 were as previously published 4 . In addition, the following primers were used: Mmp3 forward 5′-CCTGATGT-TGGTGGCTTCA-3′, reverse 5′-TC CTGTAGGTGATGTGGGATTTC-3′; Pparg forward 5′-TCTTCCATCAC GGAGAGGTC-3′, reverse 5′-GATGCACTGCCTATGAGC-AC-3′; Cebpa forward 5′-TTGTTTGGCTTTATCTCGGC-3′, reverse 5′-CCAAGAAG-TC GGTGGACAAG-3′; Il1a forward 5′-TCAACCAAACTATATATATCAGGAT GT GG-3′, reverse 5′-CGAGTAGGCATACATGTCAAATTTTAC-3′; Tnfa forward 5′-AGGGTCTGGGCCATAGAACT-3′, reverse 5′-CAGCCTCTT CTCATTCCTGC-3′; Agtr1a forward 5′-AAGGGCCATTTTGCTTT-TCT-3′, reverse 5′-AACTCACAGCAACCCTCCAA-3′; Sur2a forward 5′-CAATG GAGGCTGTCAGAACA-3′, reverse 5′-GGAGCTGACAGACACGAACA-3′; and Igfbp5 forward 5′-ATACAACCCAGAACGCCAGCT-3′, reverse 5′-ACC TGGGCTATGCACTTGATG-3′. SA-β-Gal staining, electron microscopy and X-ray elemental analysis. For SA-β-Gal staining on kidney cryosections, tissue was embedded in OCT, sectioned at 10 μm thickness, and air-dried. After rehydration in PBS, staining was performed using the Cell Signaling kit (9860) with a 12-min fixation followed by incubating in the staining solution at 37 °C for 12 h. Whole mount SA-β-Gal stainings on fat, kidney and heart were performed using a kit (Cell Signaling), with a 20-min fixation followed by immersing samples in the staining solution at 37 °C for 12 h (iWAT and eWAT) or 48 h (heart and kidney). Detection of X-Gal crystals by transmission electron microscopy was as previously described 45 . Specifically, X-Gal-containing whole mounts were fixed in Trump's fixative at 4 °C for 12 h and routinely processed for OsO 4 /lead staining. Images were acquired and quantification performed on a Jeol 1400+ electron microscope with 80 kV acceleration voltage. The authenticity of X-Gal crystals was confirmed by X-ray elemental analysis, whereas the specificity of crystal formation was verified using fat and heart tissue that was not stained for SA-β-Gal. To measure the percentage of X-Gal-crystal-containing cells in kidney sections of AP-or vehicle-treated mice, we screened 5 grids (>1,500 cells per grid) per treatment group for cells X-gal-positive cells at 3,000× magnification. Cells with one or more crystals and the total number of cells were counted. iWAT and the visceral pericardium were assessed similarly, with cells with one or more crystals considered to be X-Gal positive. For iWAT, we only observed crystals in stromovascular cells with morphology and perivascular location consistent with adipocyte progenitors and therefore expressed the X-Gal fraction of total cells. More than 500 total fat cells per animal were scored for iWAT (n = 4 animals per group). Total cells was estimated by extrapolating from the cellularity of five 1,500× fields. Owing to dissection and processing, the serous pericardium was lost for most samples, so the visceral pericardium alone was scored via TEM. Only ciliated epithelial cells stained positive for SA-β-Gal, therefore we expressed the X-Gal positivity of this tissue as percentage of this cell type. The entire visible pericardium on one TEM grid per animal was scored, with four animals per group. For quantitation of SA-β-Gal positive cells in GFP + and GFP − cell fractions collected from iWAT, 100 cells were scored per fraction (n = 3 animals). Tissue immunofluorescence staining and western blotting. Paraffin-embedded kidney tissue sections (5 μm) were rehydrated (2 × 10 min xylene; 2 × 5 min 100% ethanol; 1 × 5 min 95% ethanol; 1 × 5 min 70% ethanol), incubated in protease from Streptomyces griseus (Sigma, P6911; 0.75 mg ml −1 in Tris buffer, 0.05 M, pH 7.6) for 1 h at 37 °C to retrieve antigens, blocked with Rodent Block M (BioCare Medical) for 30 min, and incubated with rabbit anti-Agtr1a antibody (Novus Bio, NBP1-77078; 1:250) in antibody diluent (Dako) for 12 h at 4 °C. Western blotting on tissue lysates was performed according to standard methods, incubating the nitrocellulose membrane overnight at 4 °C with the following antibodies: Agtr1a (as above; 1:750), S6K (Cell Signaling, 2708; 1:1,000), phospho-S6K (Cell Signaling, 9234; 1:1,000), AKT (Cell Signaling, 9272; 1:1,000), and phospho-AKT S473 (Cell Signaling, 9271; 1:1,000). Quantification of p-S6K/S6K and p-AKT S473 /AKT ratios was performed as described 46, 47 . Cell culture. ATTAC MEFs were generated as previously described 4 . Western blotting for p16 Ink4a and mouse anti-actin was performed as described 48 . Growth curves were generated as previously described 48 . RNA extraction was done with a Micro RNeasy kit according to manufacturer's instructions (Qiagen). Early passage p16-3MR MEFs 8 were provided by J. Campisi and M. Demaria. Early passage homozygous p16-FLUC MEFs 49 were provided by C. Burd. MEFs were immortalized by expression of SV40 large T antigen as described 50 . The cell line genotypes were authenticated by PCR genotyping. They were not tested for mycoplasma contamination.
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Extended Data Figure 3 | ATTAC-mediated clearance of senescent cells is partial and tissue selective and attenuates expression of inflammation markers. a, Expression of the ATTAC transgene and a senescence marker panel, as determined by RT-PCR, in gastrocnemius, eye, kidney, heart (atria), spleen, lung, liver and colon (n = 4 females per group). b, Expression of Il6, Il1a and Tnfa as determined by qRT-PCR in mouse iWAT, kidney and skeletal muscle at different ages (n = 4 females per group). Il6 values are as indicated in Extended Data Fig. 1d (iWAT) and in a (kidney and gastrocnemius). Expression levels of inflammation markers in unmanipulated 18-month-old C57BL/6 females suggests that repeated vehicle injections were not a source of tissue inflammation. Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired two-tailed t-tests). Asterisks above individual bars in a denote significant changes to 2-month-old mice; asterisks above brackets denote significant differences between 18-month-old vehicle and AP-treated mice.
Extended Data Figure 5 | Senescent cell clearance delays tumour and cataract formation. a, b, Survival curves of mixed (a) and C57BL/6 (b) ATTAC mice dying of cancer (mice that had an overt tumour at time of death; only mice with lymphomas, sarcomas and carcinomas were included). Median survival (in days) and percentage increase are indicated. c, d, Incidence of macroscopically detectable neoplasms (lymphomas, sarcomas and carcinomas) at time of death in mixed (c) and C57BL/6 (d) ATTAC mice from survival cohorts. e, Survival curves of C57BL/6-129Sv-FVB mice dying without cancer (mice that had an overt tumour at time of death, including lymphoma, sarcoma and/or carcinoma, were excluded). Median survival (in days) and percentage increase are indicated. f, g, Cataract incidence for mixed (f) and C57BL/6 (g) ATTAC mouse cohorts. *P < 0.05; **P < 0.01; ***P < 0.001 (log-rank tests).
Extended Data Figure 9 | Senescent cell clearance does not alter cardiac morphology and function in 'resting' mice and AP treatment has no effect on healthspan of mice lacking the ATTAC transgene. a, Electron micrographs of X-Gal crystal containing cells in the aortic root. VSMC, vascular smooth muscle cell. Scale bars, 1 μm (main panel) and 200 nm (inset). b-g, Echocardiography measurements of heart rate (b), left ventricular mass (c), posterior wall thickness (d), left ventricular inner diameter (e), ejection fraction (f), and the fractional shortening of the heart (g) in 12-month-old untreated mice and 18-month-old ATTAC mice treated with vehicle or AP. h, Fat mass (n = 9 mice per group). 18-month-old ATTAC vehicle-treated mouse values are the same as indicated in Fig. 1 . i, iWAT and eWAT depot weight (n = 4 mice per group). 18-monthold ATTAC vehicle-treated mouse values are the same as indicated in Fig. 1. j, k , Kidney sclerosis (j) and blood urea levels (k) (n = 4 mice per group). 18-month-old ATTAC vehicle-treated mouse values are the same as indicated in Fig. 4 . l, Time to death after isoproterenol administration (n = 4 mice per group). 18-month-old ATTAC vehicle-treated mouse values are the same as indicated in Fig. 5 . Error bars indicate s.e.m. No statistically significant differences were observed using unpaired two-tailed t-tests.
